AAREYDRUGS vs NECLIFE: Stock Comparison
Aarey Drugs & Pharmaceuticals Limited vs Nectar Lifesciences Limited
Live data: 29 April 2026, 4:01 PM IST • Source: NSE and company filings
Aarey Drugs & Pharmaceuticals Limited is the larger company by market capitalisation. Aarey Drugs & Pharmaceuticals Limited shows a higher ROE, faster revenue growth and a higher ROCE, while Nectar Lifesciences Limited shows a lower P/E and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Aarey Drugs & Pharmaceuticals Limited and Nectar Lifesciences Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| Live Price | ₹90.51 | ₹13.56 |
| Day Change | -4.92% | -5.57% |
| Volume | 2.2 L | 7 L |
| 52-Week High | ₹96 | ₹21.4 |
| 52-Week Low | ₹50.31 | ₹9.3 |
| Distance from 52W High | -5.72% | -36.64% |
Valuation
| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| Market Cap | ₹221 Cr | ₹203 Cr |
| P/E Ratio | 55.36x | -0.8x |
| P/B Ratio | 1.46x | 0.4x |
| EPS | ₹1.47 | ₹-8.06 |
| Book Value | ₹48.67 | ₹42.63 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 19.8% | -3.41% |
| EPS Growth (TTM YoY) | -41.05% | 0% |
| Qtr Sales Growth | 0% | -21.9% |
| Qtr Profit Growth | 0% | -2,229% |
Profitability & Leverage
| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| ROE | 2.64% | -9.85% |
| ROCE | 6% | -5.36% |
| Net Margin | 0.84% | -11.28% |
| Operating Margin | 2.21% | — |
| Debt to Equity | 0.33x | 0x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | AAREYDRUGS | NECLIFE |
|---|---|---|
| Promoter Holding | 37.71%▼ 1.35 pp | 51.84% |
| FII Holding | 4.18%▲ 0.32 pp | 0.5%▼ 0.1 pp |
| DII Holding | 1.62%▲ 1.62 pp | 3.74%▼ 0.27 pp |
| Public Holding | 56.49%▼ 0.6 pp | 43.89%▲ 0.37 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aarey Drugs & Pharmaceuticals Limited and Nectar Lifesciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.